ATE481986T1 - Polynukleotidkonstrukte, pharmazeutische zusammensetzungen und verfahren zur gezielten herunterregulierung von angiogenese und zur krebstherapie - Google Patents

Polynukleotidkonstrukte, pharmazeutische zusammensetzungen und verfahren zur gezielten herunterregulierung von angiogenese und zur krebstherapie

Info

Publication number
ATE481986T1
ATE481986T1 AT02801473T AT02801473T ATE481986T1 AT E481986 T1 ATE481986 T1 AT E481986T1 AT 02801473 T AT02801473 T AT 02801473T AT 02801473 T AT02801473 T AT 02801473T AT E481986 T1 ATE481986 T1 AT E481986T1
Authority
AT
Austria
Prior art keywords
angiogenesis
regulation
methods
pharmaceutical compositions
ligand
Prior art date
Application number
AT02801473T
Other languages
English (en)
Inventor
Dror Harats
Shoshana Greenberger
Eyal Breitbart
Original Assignee
Vascular Biogenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Biogenics Ltd filed Critical Vascular Biogenics Ltd
Application granted granted Critical
Publication of ATE481986T1 publication Critical patent/ATE481986T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
AT02801473T 2001-10-19 2002-05-01 Polynukleotidkonstrukte, pharmazeutische zusammensetzungen und verfahren zur gezielten herunterregulierung von angiogenese und zur krebstherapie ATE481986T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33011801P 2001-10-19 2001-10-19
PCT/IL2002/000339 WO2003033514A1 (en) 2001-10-19 2002-05-01 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy

Publications (1)

Publication Number Publication Date
ATE481986T1 true ATE481986T1 (de) 2010-10-15

Family

ID=23288387

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02801473T ATE481986T1 (de) 2001-10-19 2002-05-01 Polynukleotidkonstrukte, pharmazeutische zusammensetzungen und verfahren zur gezielten herunterregulierung von angiogenese und zur krebstherapie

Country Status (13)

Country Link
US (4) US7585666B2 (de)
EP (3) EP1436313B1 (de)
JP (1) JP4173446B2 (de)
KR (1) KR100866117B1 (de)
CN (2) CN100506284C (de)
AT (1) ATE481986T1 (de)
AU (1) AU2002307793B2 (de)
CA (1) CA2463816C (de)
DE (1) DE60237777D1 (de)
MX (1) MXPA04003514A (de)
NZ (1) NZ532348A (de)
WO (1) WO2003033514A1 (de)
ZA (1) ZA200402756B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
BR9912053A (pt) 1998-07-13 2001-04-03 Univ Texas Processos de tratamento de câncer utilizando conjugados terapêuticos que se ligam a aminofosfolipìdios
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20070286845A1 (en) * 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US20100282634A1 (en) * 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US8039261B2 (en) 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
EP1436313B1 (de) * 2001-10-19 2010-09-22 Vascular Biogenics Ltd. Polynukleotidkonstrukte, pharmazeutische zusammensetzungen und verfahren zur gezielten herunterregulierung von angiogenese und zur krebstherapie
US7939634B2 (en) 2004-01-27 2011-05-10 Compugen Ltd. Polynucleotides encoding polypeptides and methods using same
AU2011205076B2 (en) * 2004-11-14 2012-03-15 Vascular Biogenics Ltd. Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
JP4744187B2 (ja) * 2005-05-10 2011-08-10 オリンパス株式会社 細胞観察装置
JP4843767B2 (ja) * 2005-08-31 2011-12-21 国立大学法人 岡山大学 がん細胞特異的遺伝子発現法を用いた血管新生阻害薬
GB0818649D0 (en) * 2008-10-10 2008-11-19 Nat Univ Ireland Treatment of proliferative disorders with trail
MX338931B (es) 2010-01-05 2016-05-06 Vascular Biogenics Ltd Composiciones y metodo para tratar gliobastoma (gbm).
MX342641B (es) 2010-01-05 2016-10-07 Vascular Biogenics Ltd Metodos para uso de un agente adenoviral anti-angiogenico especifico.
KR101989171B1 (ko) 2012-10-17 2019-06-14 바스큘라 바이오제닉스 리미티드 아데노바이러스를 사용하는 치료 방법
US9682154B2 (en) 2013-02-04 2017-06-20 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
EP3697451A1 (de) * 2017-10-20 2020-08-26 Vascular Biogenics Ltd. Diagnostische methoden für therapie mit anti-angiogenem mittel

Family Cites Families (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3835074A (en) 1973-04-26 1974-09-10 Hercules Inc Joint cement compositions
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
CH642665A5 (en) 1979-02-08 1984-04-30 Rudolf Berchtold Process for the preparation of 1-(omega-carboxyalkyl)-2-alkyl- glycero-3-phosphatides
US4329302A (en) 1980-06-27 1982-05-11 Board Of Regents, The University Of Texas System Synthetic phosphoglycerides possessing platelet activating properties
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4410237A (en) 1980-09-26 1983-10-18 Massachusetts Institute Of Technology Method and apparatus for shaping electromagnetic beams
DE3307925A1 (de) 1983-03-05 1984-09-06 A. Nattermann & Cie GmbH, 5000 Köln Neue 0-acyl-alkandiol-phospholipide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US4614796A (en) 1983-03-25 1986-09-30 Nippon Shinyaku Co., Ltd. Liposome and method of manufacture therefor
JPS60100544A (ja) 1983-11-08 1985-06-04 Ono Pharmaceut Co Ltd 新規なグリセリン誘導体，その製造方法及びその誘導体を含有する薬剤
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4793349A (en) 1984-09-10 1988-12-27 Weinrib Harry P Needle holder for surgery
US4710579A (en) 1984-11-09 1987-12-01 Takeda Chemical Industries, Ltd. 2-(acetoacetyloxy)-3-(octadecyloxy)propyl-3-trimethylammoniopropyl phosphate or a pharmaceutically acceptable salt thereof
US4827011A (en) 1984-12-10 1989-05-02 American Cyanamid Company Antihypertensive phosphate derivatives
JP2528107B2 (ja) 1985-03-15 1996-08-28 サマ−トン，ジエ−ムス ポリヌクレオチド測定試薬と方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4711512A (en) 1985-07-12 1987-12-08 Environmental Research Institute Of Michigan Compact head-up display
CA1293663C (en) 1986-01-06 1991-12-31 David Christopher Auth Transluminal microdissection device
US5061626A (en) 1986-03-24 1991-10-29 University Of Sydney Antigenic anarogues of platelet activating factor
US5314407A (en) 1986-11-14 1994-05-24 Heart Technology, Inc. Clinically practical rotational angioplasty system
US4866042A (en) 1987-11-18 1989-09-12 Neuwelt Edward A Method for the delivery of genetic material across the blood brain barrier
DE3807123A1 (de) 1988-03-04 1989-09-14 Boehringer Mannheim Gmbh Substrate fuer phospholipasen
DE8904026U1 (de) 1988-04-20 1989-05-24 Schneider (Europe) AG, Zürich Katheter zum Rekanalisieren von verengten Gefäßen
DE3821544C2 (de) 1988-06-25 1994-04-28 H Prof Dr Med Just Dilatationskatheter
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5087244A (en) 1989-01-31 1992-02-11 C. R. Bard, Inc. Catheter and method for locally applying medication to the wall of a blood vessel or other body lumen
US4994033A (en) 1989-05-25 1991-02-19 Schneider (Usa) Inc. Intravascular drug delivery dilatation catheter
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
US5237451A (en) 1989-11-17 1993-08-17 Minnesota Mining And Manufacturing Company Beam shaping system using diffraction
US5082629A (en) 1989-12-29 1992-01-21 The Board Of The University Of Washington Thin-film spectroscopic sensor
US5049132A (en) 1990-01-08 1991-09-17 Cordis Corporation Balloon catheter for delivering therapeutic agents
US5053041A (en) 1990-03-12 1991-10-01 Ansari Shapoor S Vessel holder
ES2019552A6 (es) 1990-04-11 1991-06-16 Menarini Lab Procedimiento para la preparacion de glicerofosfolipidos.
US5364393A (en) 1990-07-02 1994-11-15 Heart Technology, Inc. Tissue dissipative recanalization catheter
US5180366A (en) 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
CA2108144A1 (en) 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
US5213576A (en) 1991-06-11 1993-05-25 Cordis Corporation Therapeutic porous balloon catheter
US5766151A (en) 1991-07-16 1998-06-16 Heartport, Inc. Endovascular system for arresting the heart
US5224198A (en) 1991-09-30 1993-06-29 Motorola, Inc. Waveguide virtual image display
US5306250A (en) 1992-04-02 1994-04-26 Indiana University Foundation Method and apparatus for intravascular drug delivery
US5368566A (en) 1992-04-29 1994-11-29 Cardiovascular Dynamics, Inc. Delivery and temporary stent catheter having a reinforced perfusion lumen
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
DE4225553C1 (de) 1992-08-03 1994-05-11 Michael Dr Rudolf Ballonkatheter
US5447497A (en) 1992-08-06 1995-09-05 Scimed Life Systems, Inc Balloon catheter having nonlinear compliance curve and method of using
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5336178A (en) 1992-11-02 1994-08-09 Localmed, Inc. Intravascular catheter with infusion array
US5614502A (en) 1993-01-15 1997-03-25 The General Hospital Corporation High-pressure impulse transient drug delivery for the treatment of proliferative diseases
WO1994021320A1 (en) 1993-03-15 1994-09-29 Advanced Cardiovascular Systems, Inc. Fluid delivery catheter
JP3623250B2 (ja) 1993-06-23 2005-02-23 オリンパス株式会社 映像表示装置
DE4324218A1 (de) 1993-07-19 1995-01-26 Bavaria Med Tech Manschettenkatheter
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5635385A (en) 1993-09-15 1997-06-03 Temple University-Of The Commonwealth System Of Higher Education Multi-unit ribozyme inhibition of oncogene gene expression
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
US6579697B1 (en) * 1995-05-11 2003-06-17 Yeda Research And Development Co. Ltd. Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors
US8715645B2 (en) * 1994-05-27 2014-05-06 The Regents Of The University Of Colorado Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
JPH07326065A (ja) 1994-05-27 1995-12-12 Hitachi Ltd 光情報処理装置
US5747340A (en) * 1994-06-03 1998-05-05 Syntex (U.S.A.) Inc. Targeted gene expression using preproendothelin-1 promoters
US5906827A (en) 1994-06-03 1999-05-25 Creative Biomolecules, Inc. Matrix for the manufacture of autogenous replacement body parts
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
AU3216695A (en) 1994-08-29 1996-03-22 University Of North Carolina At Chapel Hill, The Lipid analogs for treating viral infections
US5734039A (en) 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes
US5506929A (en) 1994-10-19 1996-04-09 Clio Technologies, Inc. Light expanding system for producing a linear or planar light beam from a point-like light source
US5707385A (en) 1994-11-16 1998-01-13 Advanced Cardiovascular Systems, Inc. Drug loaded elastic membrane and method for delivery
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5712149A (en) * 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US5660855A (en) 1995-02-10 1997-08-26 California Institute Of Technology Lipid constructs for targeting to vascular smooth muscle tissue
US5792453A (en) 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US6254862B1 (en) 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US5746716A (en) 1995-07-10 1998-05-05 Interventional Technologies Inc. Catheter for injecting fluid medication into an arterial wall
JP2002515856A (ja) 1995-10-11 2002-05-28 タラリア セラピューティックス インコーポレーテッド リポソーム組成物およびそれらの利用方法
US5916763A (en) 1995-11-09 1999-06-29 The Regents Of The University Of California Promoter for VEGF receptor
US6825980B2 (en) 1995-12-18 2004-11-30 Metrologic Instruments, Inc. DOE-based systems and devices for producing laser beams having modified beam characteristics
US5976800A (en) * 1996-06-28 1999-11-02 The Regents Of The University Of California Enhancement of cancer cell death
EP0835673A3 (de) 1996-10-10 1998-09-23 Schneider (Usa) Inc. Katheter für Gewebedilatation und Arzneimittelverabreichung
JP2001503273A (ja) 1996-11-08 2001-03-13 オクラホマ メディカル リサーチ ファウンデーション Ｅｐｃｒ制御エレメントにより調節される内皮特異的発現
NZ336381A (en) * 1996-12-30 2000-11-24 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
TR199902068T2 (xx) * 1997-02-28 1999-12-21 Boehringer Ingelheim Pharmaceuticals, Inc. �ltihap h�crelerinin gen tedavisi ile kendi kendini d�zenleyen apoptozu.
US6206917B1 (en) 1997-05-02 2001-03-27 St. Jude Medical, Inc. Differential treatment of prosthetic devices
ES2320603T3 (es) 1997-07-30 2009-05-25 Emory University Sistemas de expresion, vectores, adn, proteinas de mineralizacion osea novedosos.
US6204055B1 (en) 1999-04-12 2001-03-20 Isis Pharmaceuticals, Inc. Antisense inhibition of Fas mediated signaling
EP0909532A1 (de) 1997-10-16 1999-04-21 Development Center For Biotechnology Umweltfreundliches poröses Material enthaltend vorteilhafte Nematoden und dessen Herstellung
US6183737B1 (en) 1997-10-30 2001-02-06 The General Hospital Corporation Bonding of cartilage pieces using isolated chondrocytes and a biological gel
US5882893A (en) * 1997-12-04 1999-03-16 Millennium Pharmaceuticals, Inc. Nucleic acids encoding muscarinic receptors and uses therefor
US6027514A (en) 1997-12-17 2000-02-22 Fox Hollow Technologies, Inc. Apparatus and method for removing occluding material from body lumens
US6699231B1 (en) 1997-12-31 2004-03-02 Heartport, Inc. Methods and apparatus for perfusion of isolated tissue structure
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
ATE254291T1 (de) 1998-04-02 2003-11-15 Elop Electrooptics Ind Ltd Optische holographische vorrichtungen
US6364856B1 (en) 1998-04-14 2002-04-02 Boston Scientific Corporation Medical device with sponge coating for controlled drug release
US6180355B1 (en) * 1998-05-07 2001-01-30 University Of Maryland, Baltimore Method for diagnosing and treating chronic pelvic pain syndrome
US6280411B1 (en) 1998-05-18 2001-08-28 Scimed Life Systems, Inc. Localized delivery of drug agents
US6206283B1 (en) 1998-12-23 2001-03-27 At&T Corp. Method and apparatus for transferring money via a telephone call
US20030060876A1 (en) 2000-09-28 2003-03-27 Amir Loshakove Graft delivery system
GB9813919D0 (en) * 1998-06-26 1998-08-26 Hoffmann La Roche Hydrazine derivatives
US6239151B1 (en) * 1998-06-26 2001-05-29 Hoffmann-La Roche Inc. Compounds as inhibitor of tumor necrosis factor alpha release
US6036700A (en) 1998-07-14 2000-03-14 Ethicon Endo-Surgery, Inc. Surgical anastomosis instrument
AU5318299A (en) * 1998-07-27 2000-02-21 Valentis, Inc. Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same
DE19838837A1 (de) 1998-08-27 2000-03-02 Boehringer Ingelheim Int Zellspezifische Promoter des Entkopplungsproteins 3
JP2000070367A (ja) 1998-08-27 2000-03-07 Shimadzu Corp 針無注射器
US6576697B1 (en) * 1998-09-02 2003-06-10 Thayer A. Brown, Jr. Malleable high density polymer material
US6280414B1 (en) 1998-09-30 2001-08-28 Medtronic Ave, Inc. Method and apparatus for local delivery of therapeutic agent
JP3622556B2 (ja) 1999-02-23 2005-02-23 セイコーエプソン株式会社 照明光学系および投写型表示装置
US6743196B2 (en) 1999-03-01 2004-06-01 Coaxia, Inc. Partial aortic occlusion devices and methods for cerebral perfusion augmentation
CA2339900A1 (fr) 1999-06-08 2000-12-14 Transgene S.A. Composition destinee a la mise en oeuvre d'un traitement cytotoxique, notamment antitumoral ou antiviral, chez un mammifere
IL130608A0 (en) 1999-06-23 2000-06-01 Compugen Ltd Novel nucleic and amino acid sequence
US6545048B1 (en) * 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6299622B1 (en) 1999-08-19 2001-10-09 Fox Hollow Technologies, Inc. Atherectomy catheter with aligned imager
US6447525B2 (en) 1999-08-19 2002-09-10 Fox Hollow Technologies, Inc. Apparatus and methods for removing material from a body lumen
US6638233B2 (en) 1999-08-19 2003-10-28 Fox Hollow Technologies, Inc. Apparatus and methods for material capture and removal
US6348583B1 (en) 1999-08-30 2002-02-19 Bio-Rad Laboratories, Inc. Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids
US6733513B2 (en) 1999-11-04 2004-05-11 Advanced Bioprosthetic Surfaces, Ltd. Balloon catheter having metal balloon and method of making same
JP4829454B2 (ja) 1999-11-30 2011-12-07 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティ・オブ・アリゾナ 放射線感受性リポソーム
US6344027B1 (en) 1999-12-08 2002-02-05 Scimed Life Systems, Inc. Needle-less injection apparatus and method
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
US6376244B1 (en) 1999-12-29 2002-04-23 Children's Medical Center Corporation Methods and compositions for organ decellularization
US6479064B1 (en) 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6265216B1 (en) 2000-01-20 2001-07-24 Isis Pharmaceuticals, Inc. Antisense modulation of cot oncogene expression
US6629953B1 (en) 2000-02-18 2003-10-07 Fox Hollow Technologies, Inc. Methods and devices for removing material from a vascular site
US6866864B2 (en) * 2000-03-20 2005-03-15 Ahmed Mousa Compositions and methods of use in the treatment of angiogenesis and vascular-related disorders
US6652583B2 (en) 2000-04-07 2003-11-25 Rhode Island Hospital Cardiac valve replacement
US6716190B1 (en) 2000-04-19 2004-04-06 Scimed Life Systems, Inc. Device and methods for the delivery and injection of therapeutic and diagnostic agents to a target site within a body
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
SE0001894D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab Medical device
US7030099B2 (en) 2000-07-21 2006-04-18 Research Corporation Technologies, Inc. Tumor specific promoters of the midkine gene that allow for selective expression in P53-inactivated cells
IL138766A0 (en) 2000-09-28 2001-10-31 Cyclo Science Ltd Constant pressure apparatus for the administration of fluids intravenously
JP2002122783A (ja) 2000-10-13 2002-04-26 Olympus Optical Co Ltd 観察光学系及び撮像光学系及びそれを用いた装置
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
ES2338529T3 (es) 2000-11-17 2010-05-10 Vascular Biogenics Ltd. Prometores que exiben especificidad por celulas endoteliales y metodos para su utilizacion.
US7067649B2 (en) 2000-11-17 2006-06-27 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8039261B2 (en) 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20070286845A1 (en) 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20100282634A1 (en) * 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US6623452B2 (en) 2000-12-19 2003-09-23 Scimed Life Systems, Inc. Drug delivery catheter having a highly compliant balloon with infusion holes
US6544223B1 (en) 2001-01-05 2003-04-08 Advanced Cardiovascular Systems, Inc. Balloon catheter for delivering therapeutic agents
WO2002061110A2 (en) 2001-01-29 2002-08-08 Bio-Rad Laboratories, Inc. Nucleic acid derivatives
US20020107504A1 (en) 2001-02-06 2002-08-08 Gordon Lucas S. Apparatus for local drug delivery in limb
EP2338983B1 (de) 2001-02-14 2015-10-07 Anthrogenesis Corporation Regeneration und Repopulation von dezellularisierten Geweben und Kadaverorganen durch Stammzellen.
KR20020083737A (ko) 2001-04-30 2002-11-04 삼성전자 주식회사 착용형 디스플레이 시스템
US6438802B1 (en) 2001-06-07 2002-08-27 Randolph Scott Beeman Locking mechanism and method for securely fastening resilient cords and tubing
EP1446501A2 (de) 2001-06-25 2004-08-18 Buadbo APS Verfahren zur identifizierung von zelloberflächemolekulen von krebszellen und krebsspezifischen promotoren, und ihre therapeutischen verwendungen
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US20030040509A1 (en) 2001-08-06 2003-02-27 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ACE
US6833955B2 (en) 2001-10-09 2004-12-21 Planop Planar Optics Ltd. Compact two-plane optical device
EP1436313B1 (de) 2001-10-19 2010-09-22 Vascular Biogenics Ltd. Polynukleotidkonstrukte, pharmazeutische zusammensetzungen und verfahren zur gezielten herunterregulierung von angiogenese und zur krebstherapie
US20040044403A1 (en) 2001-10-30 2004-03-04 Joyce Bischoff Tissue-engineered vascular structures
EP1506285B1 (de) 2001-11-01 2010-12-08 Uab Research Foundation Kombinationen aus anti-dr5-antikörpern und anti-dr4-antikörpern und weiteren therapeutischen agentien
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
EP2292278B1 (de) 2001-11-16 2013-04-24 Children's Medical Center Corporation Verbesserung der Funktion von Organen
KR100450815B1 (ko) 2002-02-01 2004-10-01 삼성전자주식회사 조명계 및 이를 채용한 프로젝션 디스플레이 장치
US20030180268A1 (en) 2002-02-05 2003-09-25 Anthony Atala Tissue engineered construct for supplementing or replacing a damaged organ
US7247477B2 (en) 2002-04-16 2007-07-24 Technion Research & Development Foundation Ltd. Methods for the in-vitro identification, isolation and differentiation of vasculogenic progenitor cells
US6757105B2 (en) 2002-04-25 2004-06-29 Planop Planar Optics Ltd. Optical device having a wide field-of-view for multicolor images
US7023622B2 (en) 2002-08-06 2006-04-04 Dmetrix, Inc. Miniature microscope objective lens
US6805490B2 (en) 2002-09-30 2004-10-19 Nokia Corporation Method and system for beam expansion in a display device
AU2003277191A1 (en) 2002-10-01 2004-04-23 Duke University Targeted tumor therapy by use of recombinant adenovirus vectors that selectively replicate in hypoxic regions of tumors
PL219321B1 (pl) 2002-10-15 2015-04-30 Per Sonne Holm Adenowirus, kodujący go kwas nukleinowy, zawierający je układ replikacyjny, wektor, komórka i organizm, ich zastosowanie oraz środek farmaceutyczny
CN100424547C (zh) 2002-12-26 2008-10-08 三洋电机株式会社 投影式视频显示器
AU2003300676A1 (en) 2003-01-03 2004-07-29 Aurelium Biopharma Inc. Hsc70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease
US7339042B2 (en) 2003-06-09 2008-03-04 University Of Florida Research Foundation, Inc. Gene delivery to tumors
US7184617B2 (en) 2004-03-12 2007-02-27 Matsushita Electric Industrial Co., Ltd. Portable device
US7537580B2 (en) 2004-06-23 2009-05-26 Boston Scientific Scimed, Inc. Intravascular dilatation infusion catheter
WO2006006169A2 (en) 2004-07-14 2006-01-19 By-Pass, Inc. Material delivery system
CA2575163A1 (en) 2004-08-09 2006-02-23 Merck & Co., Inc. Adenoviral vector compositions
US20060056028A1 (en) 2004-09-13 2006-03-16 Wildnauer Kenneth R Apodized diffraction grating with improved dynamic range
US20060194765A1 (en) 2004-11-16 2006-08-31 Garcia Joe G N Methods and compositions using oxidized phospholipids
US7206107B2 (en) 2004-12-13 2007-04-17 Nokia Corporation Method and system for beam expansion in a display device
EP1844069A4 (de) 2005-01-28 2009-05-20 Apollo Life Sciences Ltd Moleküle und chimere moleküle davon
GB2426457A (en) 2005-05-26 2006-11-29 Leonid Shturman Balloon angioplasty device with distal protection capability
US8137977B2 (en) 2006-04-24 2012-03-20 Children's Hospital & Research Center At Oakland Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
WO2008015675A2 (en) 2006-07-31 2008-02-07 Vascular Biogenics Ltd. Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia
US20080140001A1 (en) 2006-12-12 2008-06-12 By-Pass Inc. Fluid Delivery Apparatus And Methods
WO2008152639A2 (en) 2007-06-12 2008-12-18 Bypass, Inc. Pressure pulse actuating device for delivery systems
KR20090011223A (ko) 2007-07-25 2009-02-02 삼성전자주식회사 방송처리장치 및 그 제어방법
WO2009070298A1 (en) 2007-11-28 2009-06-04 Teva Pharmaceutical Industries, Ltd. Method of delaying the onset of clinically definite multiple sclerosis
US20110083464A1 (en) 2009-10-12 2011-04-14 Craig Kettles Refrigerator with a Pullout Refrigerator Compartment
MX338931B (es) 2010-01-05 2016-05-06 Vascular Biogenics Ltd Composiciones y metodo para tratar gliobastoma (gbm).
MX342641B (es) 2010-01-05 2016-10-07 Vascular Biogenics Ltd Metodos para uso de un agente adenoviral anti-angiogenico especifico.
US20130052165A1 (en) 2010-01-12 2013-02-28 Livnat Bangio Methods of Producing Adenovirus Vectors and Viral Preparations Generated Thereby
WO2012052878A1 (en) 2010-10-19 2012-04-26 Vascular Biogenics Ltd. Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells

Also Published As

Publication number Publication date
US20040197860A1 (en) 2004-10-07
US7585666B2 (en) 2009-09-08
EP2277887A2 (de) 2011-01-26
CN101570764A (zh) 2009-11-04
CA2463816A1 (en) 2003-04-24
US7989427B2 (en) 2011-08-02
HK1067641A1 (en) 2005-04-15
WO2003033514A1 (en) 2003-04-24
EP2223932A1 (de) 2010-09-01
MXPA04003514A (es) 2004-07-23
ZA200402756B (en) 2006-05-31
US8415318B2 (en) 2013-04-09
KR20040094391A (ko) 2004-11-09
NZ532348A (en) 2006-06-30
EP1436313A1 (de) 2004-07-14
EP2277887A3 (de) 2011-02-16
EP1436313B1 (de) 2010-09-22
CN1602315A (zh) 2005-03-30
CN100506284C (zh) 2009-07-01
KR100866117B1 (ko) 2008-10-31
JP4173446B2 (ja) 2008-10-29
EP1436313A4 (de) 2006-05-03
US20110251122A1 (en) 2011-10-13
JP2005532031A (ja) 2005-10-27
DE60237777D1 (de) 2010-11-04
US20130272998A1 (en) 2013-10-17
US20080305088A1 (en) 2008-12-11
US8916378B2 (en) 2014-12-23
CA2463816C (en) 2014-07-08
AU2002307793B2 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
DE60237777D1 (de) Etzungen und verfahren zur gezielten herunterregulierung von angiogenese und zur krebstherapie
DE69435075D1 (de) , die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
TR200102191T2 (tr) HER-2/neu füzyon proteinleri.
ATE409181T1 (de) Proteomimetische verbindungen und verfahren
DE69939553D1 (de) Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
DE69838249D1 (de) Anti-apo-2 antikörper
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
DK1767546T3 (da) Angiogenese-inhiberende kimært protein og dets anvendelse
DK1240337T3 (da) Fremgangsmåder og præparater til forlængelse af elimeneringshalveringstider af bioaktive forbindelser
DE60330923D1 (de) Menschliche Koagulationsfaktor VII Polypeptide
DK0948614T3 (da) Nye ekspressionsvektorer indeholdende accessoriske molekylligandgener og deres anvendelse til immunmodulation og behandling af maligniteter og autoimmunsygdomme
DK0880970T3 (da) Anvendelse af farmaceutiske præparater der omfatter et anticytokin, til behandling af dissemineret sklerose
NO20110429L (no) Polypeptider og nukleinsyre-DNA for anvendelse innen medisin
ATE306281T1 (de) Antivirales mittel in kombination mit strahlentherapie zur verwendung in der behandlung von krebs
ATE424459T1 (de) Apo-3 ligand
DE60038631D1 (de) Modulatoren und inhibitoren von angiogenese und vaskulärer durchlässigkeit
MXPA05007940A (es) Composiciones y metodos para el tratamiento del cancer usando igsf9 y liv-1.
DE60123434D1 (de) Mit schizophrenie zusammenhängendes gen und protein
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
ATE395935T1 (de) An der oberfläche von karzinomzellen lokalisiertes colligin/hsp47
ATE414776T1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
ATE483030T1 (de) Neue polynukleotid- und polypeptidsequenzen und deren verwendungen
DE60024450D1 (de) Modulierung der angiogenese durch verwendung von anti-angiogenischen angiotensin-7 und dafür kodierende polynukleotiden zur behandlung von tumoren
ATE544784T1 (de) Als cytotoxin geeignetes fusionspolypeptid

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties